DESCRIPTION OF A HEPATITIS C TREATMENT PROGRAM CO-LOCATED AT A SYRINGE EXCHANGE PROGRAM IN NEW YORK CITY

Authors: Matthew Scherer, Anna Andel, Billy Garcia, Peter Gordon

Collaboration Between Academic Medical Center and SEP

- Washington Heights Corner Project
 - Organization providing syringe exchange and other harm reduction services to people who use drugs
 - Onsite case management, nursing care, and HCV testing grant
 - Medical exam rooms onsite
- NYP Comprehensive Health Program
 - NYP CUMC HIV/ID clinic located on 168th St. in Washington Heights
 - Designated AIDS Center with broad range of onsite services
 - Provide comprehensive HCV care for both HIV coinfected and HCV monoinfected

Program Structure

- Collaboration between CHP and Washington Heights Corner Project
 - Funded by NYS AIDS Institute grant
 - Began December 2015
- Physician on-site at SEP one day/week.
- Provide clients of the Washington Heights Corner Project who are HCV infected with HCV treatment and other medical services
- Focus on case management, support services, and adherence support

Program Structure

- Initial Visit with Linkage Manager
 - Detailed assessment of potential barriers to care
- Referred to on-site physician for full visit
 - History and physical
 - Labs drawn and sent to NYP core lab
 - Referrals for fibroscan, ultrasound, subspecialty care (incl. psych and buprenorphine) if necessary
- Initially \$10 cash card at first two visits
- Peer educators
 - Weekly HCV group education
 - Escort/Transport
 - Outreach and recruitment of new clients


Data Collection and Case Conferencing

- Run by program coordinator
- Weekly conference attended by linkage manager, peers, physician
- Discuss each patient on treatment and discuss barriers to treating those who have not yet been treated
- Data collected into spreadsheet for both QI and mandated reporting

Medication Administration

- Partnership with specialty pharmacy
- Medications delivered to safe at WHCP
- Distributed by linkage manager
 - Monthly
 - Weekly
 - DOT
 - In outreach setting

Program Statistics



Participant Characteristics

Demographic Characteristic	N (%)
Gender Male Female	29 (83%) 6 (17%)
Race/Ethnicity White African-American Latino (any race)	17 (49%) 5 (14%) 13 (37%)
HCV Genotype 1a 1b 2 3 4	20 (57%) 5 (14%) 1 (3%) 8 (23%) 1 (3%)
Fibrosis Stage F0-2 F3 F4 Unk	23 (66%) 5 (14%) 6 (17%) 1 (3%)

Participant Characteristics

- Mean age 50.6 (range 29-72)
 - 15/35 (43%) born after 1965
- 26/35 (74%) IVDU during treatment or in the 6 mo. prior
- 9/35 (26%) on OST
 - 2/9 on buprenorphine initiated during the HCV treatment
 - 7/9 on MMT
- 13/35 (37%) undomiciled

Outcomes

- Of those assessed for SVR12, 24/24 (100%) achieved SVR12
- 2 clients >12 weeks post tx lost to f/u.
 - Both had undetectable HCV VL at or near EOT
- 2 clients completed treatment <12 weeks ago
- 1 client who achieved SVR12 has since died of opioid o/d

Conclusions

- Further evidence that active PWID can be treated for HCV with SVR rates similar to clinical trials
- People need not be on OST in order to achieve SVR
- Necessity of intensive case management/peer services and embeddedness within harm reduction program

Program Staff/Acknowledgements

- Anna Andel, MPH, Program Coordinator
- Christine Fitzsimmons, RN
- Billy Garcia, Linkage to Care Specialist
- Marcus Paulino, Peer Educator
- Emma Molina, Program Coordinator
- Jimmy Ruiz, Peer Educator
- Synn Stern, RN
- Funding: NYS AIDS Institute Hepatitis C Linkage to Care Grant